Shore Capital Reiterates Buy Rating for Uniphar (LON:UPR)

Uniphar (LON:UPR)‘s stock had its “buy” rating restated by equities researchers at Shore Capital in a research note issued on Tuesday, MarketBeat.com reports.

Uniphar Price Performance

UPR opened at GBX 196.57 ($2.45) on Tuesday. The company has a debt-to-equity ratio of 119.43, a current ratio of 0.90 and a quick ratio of 0.60. The stock’s 50 day simple moving average is GBX 175.14 and its 200 day simple moving average is GBX 198.72. The firm has a market cap of £536.68 million, a price-to-earnings ratio of 1,404.07 and a beta of 0.75. Uniphar has a 1 year low of GBX 163 ($2.03) and a 1 year high of GBX 256 ($3.19).

About Uniphar

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology
manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.